NSAIDs and Aspirin, 1st ed. 2016 Recent Advances and Implications for Clinical Management
Langue : Anglais
Coordonnateur : Lanas Angel
This volume is a state-of-the art resource on the recent advances and clinical management of NSAIDs and aspirin. The text provides a thorough overview of NSAIDS and aspirin, reviewing such topics as pharmacology and mechanisms, clinical effects, and the safety and efficacy of these drugs. It also focuses on the effect of the drugs on the cardiovascular system and in the prevention of GI cancer. Practical recommendations for a safe prescription of NSAIDs are also included.
Written by experts in the field, NSAIDs and Aspirin: Recent Advances and Implications for Clinical Management is a comprehensive text of great value to gastroenterologists, rheumatologists, cardiologists, oncologists, orthopedists, trauma and internal medicine specialists.
Chemistry, Pharmacodynamics, and Pharmacokinetics of NSAIDs.- Principles, Mechanisms of Action, and Future Prospects of Anti-Inflammatory Drugs.- Efficacy of NSAIDs in the Treatment of Rheumatic Diseases.- Adverse Effects of NSAIDs in the Gastrointestinal Tract: Risk Factors of Gastrointestinal Toxicity with NSAIDs.- Adverse Effects of NSAIDs on the Cardiovascular System.- Safe Prescription of NSAIDs in Clinical Practic.- NSAIDS and Aspirin: Recent Advances and Implications for Clinical Management.- Non-Prescription Analgesic Anti-inflammatory Drugs: Efficacy and Safety.- Low-Dose Aspirin in the Cardiovascular System.- Adverse Effects of Low-Dose Aspirin in the Gastrointestinal Tract.- Aspirin in the Treatment and Prevention of Cardiovascular Disease: Need for Individual Clinical Judgments.- Molecular and Experimental Basis for COX-Inhibition in Cancer.- Clinical Effects of NSAIDs and Coxibs in Colon Cancer Prevention.- Aspirin and the Prevention of Colorectal Cancer.- A Rational Approach for the Use of NSAIDs and/or Aspirin in Cancer Prevention in the Near Future: “Balancing Risk and Benefits”.
Prof. Angel Lanas graduated in medicine from the University of Zaragoza, in Zaragoza, Spain, in 1979. He completed postgraduate training in internal medicine at Zaragoza’s University Hospital and was awarded his doctor of medicine degree from the University of Zaragoza in 1984. Prof. Lanas took a position as a research fellow at the same university before working as a gastroenterologist staff member at various Spanish hospitals between 1986 and 1999. From 1989 to 1991, Prof. Lanas also joined the Department of Gastroenterology at the University of Alabama at Birmingham, in Birmingham, Alabama, as a visiting professor. He returned to Spain in 1992 as an associate professor of medicine at the University of Zaragoza. In 1999 he became clinical chief of gastroenterology at the University Hospital and in 2006 professor of medicine at the University of Zaragoza.
Since 1987, Prof. Lanas has been the recipient of multiple research grants from various Spanish funding bodies. Hehas also received grants from private foundations and companies for research mainly focused on the adverse effects of various drugs, especially nonsteroidal anti-inflammatory drugs, on the gastrointestinal tract. He is affiliated with multiple national and international gastroenterological associations and is or has been a member of different executive committees for various international studies.
Since 2000, he has published more than 80 research and review publications in the field of gastroenterology. Prof. Lanas’ research interests include acid-, H. pylori- and NSAID-related gastrointestinal diseases. Chemoprevention of GI cancer
Focuses on trending topics in the field, including the effect of NSAIDs and aspirin on the cardiovascular system and in GI cancer prevention Provides practical recommendations for a safe prescription of NSAIDs Written by experts in the field
Date de parution : 06-2018
Ouvrage de 263 p.
17.8x25.4 cm
Date de parution : 09-2016
Ouvrage de 263 p.
17.8x25.4 cm
Thèmes de NSAIDs and Aspirin :
Mots-clés :
COX inhibition; Eicosanoid biology; Pharmacodynamics; Pharmacokinetics; coxibs
© 2024 LAVOISIER S.A.S.
